In the subgroup analysis, GDF‐15 was similarly significantly associated with outcome for solid tumours as breast cancer, lung cancer or gastrointestinal cancer; however, no association with outcome could be shown for haematological cancers as myelodysplastic or myeloproliferative diseases. Here, GDF15 is linked to myeloproliferative disorder.